

Notes:

1. The figures have been re-grouped, re-casted and re-arranged, wherever necessary.
2. The financial results have been reviewed by the Audit Committee and taken on record by the Board of Directors at their meetings held on 14th February, 2014.
3. As per clause 41 of the listing agreement, the Company has opted to publish only consolidated financial results. The stand-alone financial results are available for perusal on the Company's website as well as on the stock exchanges' websites as stated below:
www.dishmangroup.com, www.bseindia.com, and www.nse-india.com
4. The Statutory Auditors have carried out a "Limited Review" of the stand-alone financial results of the Company for the quarter ended 31st December, 2013.
5. Details of Number of Investor complaints for the quarter ended 31st December, 2013: beginning - NIL, received- 6, resolved – 6, pending- NIL as at 31st December, 2013.
6. The Company's wholly owned subsidiary in China, namely, Dishman Pharma & Chemical (Shanghai) Company Limited has attained improved performance during the quarter under these results. In view of the present status of the operations and considering the projections of the subsidiary's business, the management is expecting full realisation of the value of the Company's financial exposure as at December 31, 2013.
7. The business segments of the Company comprise the followings:

Segment	Description of the activity
CRAMS	Contract Research and Manufacturing Segment under long term supply agreements
OTHERS	Bulk Drugs, Intermediates, Quats, Speciality Chemicals and Traded Goods

8. Consolidated financial results comprise the results of the parent Company, Dishman Pharmaceuticals and Chemicals Limited and its subsidiaries viz. Dishman Europe Limited., Dishman USA Inc., Dishman International Trading (Shanghai) Co. Ltd., Dishman Switzerland Limited, Dishman Pharma Solutions AG, Switzerland, Dishman Pharmaceuticals & Chemicals (Shanghai) Co. Ltd., Innovative Ozone Services Inc. (IO₃S), Dishman Netherlands B. V. (formerly known as "Pharma Syn B. V."), Cohecie Fine Chemicals B.V. (formerly known as "Dishman Holland B.V."), Carbogen Amcis Ltd. (formerly known as "Synprotec DCR Ltd."), CARBOGEN AMCIS AG, Carbogen Amcis (India) Limited, Dishman Australasia Pty. Ltd., Dishman Care Ltd., Dishman Middle East (FZE), Dishman Japan Limited (85% holding by Dishman), two joint venture Companies., namely Schutz Dishman Biotech Ltd.(22.33% holding by Dishman), and Dishman Arabia Ltd., (50% holding by Dishman) and one associate company namely, Bhadr-Raj Holdings Pvt. Ltd. (40% holding by Dishman) as per relevant Accounting Standards.

On behalf of the Board of Directors

Place: Ahmedabad
Date: 14th February, 2014

Janmejy R. Vyas
Chairman & Managing Director